|
Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC). |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol Myers Squibb; Janssen; Janssen |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |